Select Your Region
America
Europe
Africa
Global
A clinical trial to compare atezolizumab plus bevacizumab with active surveillance in people who have been treated for hepatocellular carcinoma (or HCC) through surgery or ablation, but who are at high risk of their HCC coming back.
A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
- Cancer
- Hepatocellular Carcinoma (HCC)
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:
Active, not recruiting
This trial runs in
Countries
- Australia
- Austria
- Belgium
- Brazil
- Canada
- China
- Costa Rica
- Czechia
- France
- Germany
- Hong Kong
- Italy
- Japan
- Mexico
- Netherlands
- New Zealand
- Peru
- Poland
- Russia
- Singapore
- South Korea
- Spain
- Taiwan
- Thailand
- Turkey
- United States
Trial Identifier:
NCT04102098 2019-002491-14 WO41535
Trial Summary
This study will evaluate the efficacy and safety of adjuvant therapy with atezolizumab plus bevacizumab compared with active surveillance in participants with completely resected or ablated hepatocellular carcinoma (HCC) who are at high risk for disease recurrence.
Hoffmann-La Roche
Sponsor
Phase 3
Phase
NCT04102098,WO41535,2019-002491-14
Trial Identifier
All
Gender
≥18 Years
Age
No
Healthy Volunteers
How does the IMbrave050 clinical trial work?
This clinical trial is recruiting people with a type of cancer called hepatocellular carcinoma (or HCC) that was successfully removed through surgery or ablation. In order to take part, patients must be at high risk of their HCC coming back.
The purpose of this clinical trial is to compare the effects, good or bad, of atezolizumab plus bevacizumab with active surveillance (current standard of care) in patients who previously had HCC to see which is better at stopping or delaying their HCC from coming back. If you take part in this clinical trial, you will receive either atezolizumab and bevacizumab or you will be placed under active surveillance.
How do i take part in this clinical trial?
To be able to take part in this clinical trial, you must have previously had HCC that was successfully removed through surgery or ablation, but be at high risk for your HCC to come back.
You must not have any remaining HCC cells and you cannot join the trial if you are pregnant or breastfeeding.
If you think this clinical trial may be suitable for you and would like to take part, please talk to your doctor. If your doctor thinks that you might be able to take part in this clinical trial, he/she may refer you to the closest clinical trial doctor. They will give you all the information you need to make your decision about taking part in the clinical trial. You can also find the clinical trial locations on this page.
You will have some initial tests to make sure you will be able to take the treatments given in this clinical trial. Some of these tests or procedures may be part of your regular medical care. They may be done even if you do not take part in the clinical trial. If you have had some of the tests recently, they may not need to be done again.
Before starting the clinical trial, you will be told about any risks and benefits of taking part in the trial. You will also be told what other treatments are available so that you may decide if you still want to take part.
While taking part in the clinical trial, both men and women (if you are not currently pregnant but can become pregnant) will need to either not have heterosexual intercourse or take contraceptive medication for safety reasons.
What treatment will i be given if i join this clinical trial?
Everyone who joins this clinical trial will be split into 2 groups randomly (like flipping a coin) and either:
- given atezolizumab plus bevacizumab as an infusion into your vein every 3 weeks
- OR placed under active surveillance (you will be seen every 6 weeks for tests and monitoring but will not be given any treatment)
You will have an equal chance of being placed in any group.
If you are placed under active surveillance and your HCC comes back, you may be offered the chance to be treated with atezolizumab and bevacizumab.
How often will i be seen in follow-up appointments, and for how long?
You will be given the clinical trial treatment or placed under active surveillance for 12 months (or 17 cycles, whichever occurs first) or until your HCC comes back. If your HCC has not come back at the end of 12 months (or 17 cycles, whichever occurs first), you will be seen every 12 weeks until your HCC comes back. You are free to leave this clinical trial at any time. If your HCC comes back, you will still be contacted regularly by the clinical trial doctor every 12 weeks. These checks will assess your general wellbeing and will see if you are being given other treatments for HCC.
What happens if i am unable to take part in this clinical trial?
If this clinical trial is not suitable for you, you will not be able to take part. Your doctor will suggest other clinical trials that you may be able to take part in or other treatments that you can be given. You will not lose access to any of your regular care.
For more information about this clinical trial see the For Expert tab on the specific ForPatient page or follow this link to ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04102098
Trial-identifier: NCT04102098
Trial Summary
This study will evaluate the efficacy and safety of adjuvant therapy with atezolizumab plus bevacizumab compared with active surveillance in participants with completely resected or ablated hepatocellular carcinoma (HCC) who are at high risk for disease recurrence.
Hoffmann-La Roche
Sponsor
Phase 3
Phase
NCT04102098,WO41535,2019-002491-14
Trial Identifier
Atezolizumab, Bevacizumab
Treatments
Carcinoma, Hepatocellular
Condition
Official Title
A Phase III, Multicenter, Randomized, Open-Label Study of Atezolizumab (Anti-PD-L1 Antibody) Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
Eligibility Criteria
All
Gender
≥18 Years
Age
No
Healthy Volunteers
Inclusion Criteria
- Participants with a first diagnosis of HCC who have undergone either a curative resection or ablation (radiofrequency ablation [RFA] or microwave ablation [MVA] only) within 4-12 weeks prior to randomization
- Documented diagnosis of HCC that has been completely resected or ablated (RFA or MVA only)
- Absence of major macrovascular invasion (except Vp1/Vp2) and extrahepatic spread
- Absence of extrahepatic spread as confirmed by CT or MRI scan of the chest, abdomen, pelvis, and head prior to and following curative procedure
- Full recovery from surgical resection or ablation within 4 weeks prior to randomization
- High risk for HCC recurrence after resection or ablation
- For patients who received post-operative transarterial chemoembolization: full recovery from the procedure within 4 weeks prior to randomization
- For patients with resected HCC, availability of a representative baseline tumor tissue sample
- ECOG Performance Status of 0 or 1
- Child-Pugh Class A status
- Adequate hematologic and end-organ function
- For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods
- For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm
Exclusion Criteria
- Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC
- Evidence of residual, recurrent, or metastatic disease at randomization
- Clinically significant ascites
- History of hepatic encephalopathy
- Prior bleeding event due to untreated or incompletely treated esophageal and/or gastric varices within 6 months prior to randomization
- Have received more than 1 cycle of adjuvant TACE following surgical resection
- Active or history of autoimmune disease or immune deficiency
- History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan
- Significant cardiovascular disease within 3 months prior to Day 1 of Cycle 1, unstable arrhythmia, or unstable angina
- History of malignancy other than HCC within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death
- Active tuberculosis
- Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications
- Pregnant or breastfeeding, or intending to become pregnant during the study or within 5 months after the final dose of atezolizumab or within 6 months after the final dose of bevacizumab. Women of childbearing potential must have a negative serum pregnancy test result within 14 days prior to Day 1 of Cycle 1.
- Co-infection with HBV and HCV
- Co-infection with HBV and hepatitis D viral infection
- Clinical significant uncontrolled or symptomatic hypercalcemia
- Any treatment for HCC prior to resection or ablation, including systemic therapy and locoregional therapy such as TACE
- Treatment with systemic immunostimulatory or immunosuppressive agents
- Inadequately controlled arterial hypertension
- History of hypertensive crisis or hypertensive encephalopathy
- Significant vascular disease
- Evidence of bleeding diathesis or significant coagulopathy
- Current or recent use of aspirin or full-dose oral or parenteral anticoagulants
- Core biopsy within 3 days of Day 1 of Cycle 1
- History of GI fistula, GI perforation, or intra-abdominal abscess
- Serious non-healing or dehiscing wound
- Major surgical procedure within four weeks
- Chronic daily treatment with a non-steroidal anti-inflammatory drug
For the latest version of this information please go to www.forpatients.roche.com